Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

Digestive Diseases and Sciences

Volumn 60, Issue 10, 2015, Pages 3075-3084

  Taxonera, Carlos ^a   Barreiro de Acosta, Manuel ^b   Calvo, Marta ^c   Saro, Cristina ^d   Bastida, Guillermo ^e   Martín Arranz, María D ^f   Gisbert, Javier P ^g,h   García Sánchez, Valle ⁱ   Marín Jiménez, Ignacio ^j   Bermejo, Fernando ^k   Chaparro, María ^g,h   Ponferrada, Ángel ^l   Martínez Montiel, María P ^m   Pajares, Ramón ⁿ   de Gracia, Celia ^j   Olivares, David ^a   Alba, Cristina ^a   Mendoza, Juan L ^a   Fernández Blanco, Ignacio ^o  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL DE CABUEÑES   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ UNIVERSITY OF CÓRDOBA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^l HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^o Hospital Moncloa   (Spain)

more..

Author keywords

Cohort study; Colectomy; Dose escalation; Dose optimization; Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; COLON RESECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; LYMPHOCYTIC MENINGITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PSORIASIS; REMISSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; CLINICAL TRIAL; COLITIS, ULCERATIVE; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; EVALUATION STUDY; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME;

ADULT; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942191102     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3735-4     Document Type: Article

References (29)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
2. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for UC: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617–2625.
3. Rostholder E, Ahmed A, Cheifetz AS, et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther. 2012;35:562–567.
4. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18:201–211.
5. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.
6. Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13:531–538.
7. Taxonera C, Olivares D, Mendoza JL, et al. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol. 2014;20:9170–9177.
8. Ma C, Huang V, Fedorak DK, Kroeker KI, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol. 2014;. doi:10.1097/MCG.0000000000000265.
9. Yamada S, Yoshino T, Matsuura M, et al. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol. 2014;14:80. doi:10.1186/1471-230X-14-80.
10. Magro F, Rodrigues-Pinto E, Lopes S, et al. Earlier need of infliximab intensification in ulcerative colitis than in Crohn’s disease. J Crohns Colitis. 2014;8:1331–1332.
11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:35–36.
12. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.
13. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413.
14. Cesarini M, Katsanos K, Papamichael K, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46:135–139.
15. Katz L, Gisbert JP, Manogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012;18:2026–2033.
16. Filippi J, Allen PB, Hébuterne X, et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets. 2011;12:1440–1447.
17. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–1260.
18. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400.
19. Ferrante M, Vermiere S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn’s Colitis. 2008;2:219–225.
20. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.
21. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013;146:96–109.
22. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
23. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199–212.
24. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn’s Colitis. 2010;4:355–366.
25. Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340–348.
26. Huang VW, Prosser C, Kroeker KI, Wang H, et al. Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy. Inflamm Bowel Dis. 2015;21:1359–1367.
27. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19:2568–2576.
28. Steenholdt C, Enevold C, Ainsworth MA, et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2012;36:650–659.
29. Medrano LM, Taxonera C, Márquez A, et al. Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab. Hum Immunol. 2014;75:71–75.